Jennifer Lew serves as Executive Vice President and Chief Financial Officer at Annexon, Inc., a clinical-stage biopharmaceutical company focused on developing therapies for neuroinflammatory diseases of the complement system. In this role, she oversees all aspects of the company's financial operations, including accounting, financial planning and analysis, treasury, tax, and investor relations. Lew plays a pivotal role in supporting Annexon's pipeline advancement, strategic partnerships, and capital-raising efforts to drive the company toward commercialization of its innovative treatments. With over 25 years of experience in finance and accounting within the biotechnology and pharmaceutical sectors, Lew brings a proven track record of guiding companies through transformative milestones. Prior to joining Annexon in 2022, she was Chief Financial Officer at Reata Pharmaceuticals, where she led the company's initial public offering, subsequent financings, and eventual acquisition by Biogen for $7.3 billion. Her earlier career includes senior finance positions at Relypsa (acquired by Galapagos), Onyx Pharmaceuticals (acquired by Amgen), and Genentech, where she honed expertise in SEC reporting, mergers and acquisitions, and operational finance. Lew's achievements include successfully navigating multiple IPOs, strategic transactions, and growth phases in dynamic biotech environments. Her strategic acumen has been instrumental in optimizing financial structures and fostering investor confidence, positioning her as a key leader in Annexon's pursuit of breakthrough therapies for devastating neurological disorders.